Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Waldenström Macroglobulinemia (WM) is a rare form of non-Hodgkin lymphoma with great heterogeneity, and data on the role of D-dimer in the progression of WM are limited. We retrospectively searched medical records for 110 newly diagnosed WM patients who were admitted to the department of hematology of the First Affiliated Hospital of Nanjing Medical University from January 2009 to December 2018. Univariate and multivariate analyses were used to assess prognostic factors for overall survival (OS) and progression-free survival (PFS). Characteristics associated with elevated D-dimer level in WM patients were high serum beta-2 macroglobulin, elevated serum lactic dehydrogenase, cytogenetic abnormalities and late stage of the international stage system of WM. Patients with D-dimer >0.55 mg/L had worse OS and PFS. In conclusion, high level of D-dimer was associated with poor survival and acted as a negative predictor for untreated WM patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2019.1709837 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction Chronic Obstructive Pulmonary Disease (COPD) is increasingly recognized not only as a pulmonary condition but as a systemic disorder with significant cardiovascular implications. Acute exacerbations of COPD (AECOPD) further elevate this risk, potentially through a heightened prothrombotic state. This study aimed to evaluate and compare the levels of select prothrombotic biomarkers - fibrinogen, C-reactive protein (CRP), D-dimer, von Willebrand Factor (vWF), homocysteine, lactate dehydrogenase (LDH), and platelet-to-lymphocyte ratio (PLR) - in patients with stable COPD and AECOPD, and to assess their diagnostic and prognostic significance.
View Article and Find Full Text PDFRandom forest-based predictor selection and pneumonia risk probability assessment in acute respiratory infections: A cross-sectional study in Chongqing, China, 2023-2024.
Biosaf Health
August 2025
Public Health Emergency Management Innovation Center, School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of Pathogen Infection Prevention and Control (Pek
Progression of acute respiratory infection (ARI) to pneumonia increases severity and healthcare burden. Limited evidence exists on using machine learning to identify predictors from demographics, clinical, and pathogen detection data. This study aimed to identify pneumonia predictors in ARI patients using machine learning methods.
View Article and Find Full Text PDFOverall hemostatic potential as a marker of subclinical hypercoagulability in treated psoriasis patients.
Front Med (Lausanne)
August 2025
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Background: Psoriasis is associated with increased cardiovascular risk, possibly mediated by inflammation-induced hemostatic dysregulation and hypercoagulability. However, these changes are often difficult to detect with conventional markers.
Objectives: To assess hypercoagulability in patients with psoriasis using the Overall Hemostatic Potential (OHP) test, a global integrative test for coagulation and fibrinolysis.
Atypical clinical presentation associated with Castleman disease: a case report and review of the literature.
Front Med (Lausanne)
August 2025
Department of Pathology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Background: Castleman disease (CD) is a group of rare and complicated diseases characterized by systemic inflammation, lymphadenopathy, and multiorgan involvement. It is often misdiagnosed as an infection, an autoimmune disease, or a malignant cancer.
Case Presentation: In this case, we report a 33-year-old Chinese male patient who was diagnosed with idiopathic multicentric Castleman disease (iMCD).
Temporal Patterns and Risk Factors for Pulmonary Embolism Associated with Anti-Tumor Therapies in Patients with Lung Cancer.
Ann Vasc Surg
September 2025
Department of Oncology, Anhui Medical University Clinical College of Chest &Anhui Chest Hospital, Hefei, 230022, People's Republic of China.
Objective: This study aimed to characterize the association between pulmonary embolism (PE) onset and various anti-tumor therapeutic approaches in patients with lung cancer, with the goal of identifying potential high-risk populations.
Methods: A retrospective analysis was conducted on clinical records from 2019 to 2025, among the 84,000 inpatients with lung cancer, 106 patients developed PE during hospitalization for anti-tumor treatment, who were confirmed using spiral computed tomography (CT) or pulmonary angiography per CTS (2018) and NEJM (2010) criteria. Data were collected on patient demographics, cancer staging, treatment type, and time to PE onset.